On the public citation graph
The inducible caspase-9 suicide gene system as a “safety switch” to limit on-target, off-tumor toxicities of chimeric antigen receptor T cells
0 signed · 467 inferred · view as graph
Inferred edges come from two machine sources: sweeps of open repository metadata (mostly SSRN and Zenodo), and a bulk OpenAlex citation snapshot. Every row below is labelled with the one it came from. Neither is a complete citation index — absence here is not evidence of absence.
Is this your work? Sign in with ORCID and put your name on the
claims that are yours.
Reference health. See whether every reference in this work resolves to a
known work and none has been retracted — and get a dated CiteStamped
badge you can embed.
What this work says
Outgoing claims: the papers this work cites, builds on, or argues with.
inferredcites →https://doi.org/10.1002/(sici)1096-8652(199912)62:4<247::aid-ajh9>3.0.co;2-topenalex-snapshot
Tumor lysis syndrome occurring after the administration of rituximab in lymphoproliferative disorders: High-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia
inferredcites →https://doi.org/10.1007/s00262-008-0515-4openalex-snapshot
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
inferredcites →https://doi.org/10.1007/s10637-012-9801-2openalex-snapshot
Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors
inferredcites →https://doi.org/10.1016/j.bbmt.2007.04.005openalex-snapshot
Inducible Caspase 9 Suicide Gene to Improve the Safety of Allodepleted T Cells after Haploidentical Stem Cell Transplantation
inferredcites →https://doi.org/10.1016/j.bbmt.2010.03.014openalex-snapshot
Antitransgene Rejection Responses Contribute to Attenuated Persistence of Adoptively Transferred CD20/CD19-Specific Chimeric Antigen Receptor Redirected T Cells in Humans
inferredcites →https://doi.org/10.1016/j.pain.2010.01.024openalex-snapshot
Anti-GD2 with an FC point mutation reduces complement fixation and decreases antibody-induced allodynia
inferredcites →https://doi.org/10.1016/j.ymthe.2005.04.016openalex-snapshot
A chimeric T cell antigen receptor that augments cytokine release and supports clonal expansion of primary human T cells
inferredcites →https://doi.org/10.1016/s1470-2045(09)70074-9openalex-snapshot
Infusion of suicide-gene-engineered donor lymphocytes after family haploidentical haemopoietic stem-cell transplantation for leukaemia (the TK007 trial): a non-randomised phase I–II study
inferredcites →https://doi.org/10.1038/35074122openalex-snapshot
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
inferredcites →https://doi.org/10.1038/leu.2010.75openalex-snapshot
Engineering CD19-specific T lymphocytes with interleukin-15 and a suicide gene to enhance their anti-lymphoma/leukemia effects and safety
inferredcites →https://doi.org/10.1038/leu.2012.142openalex-snapshot
T-cell receptor diversity prevents T-cell lymphoma development
inferredcites →https://doi.org/10.1038/mt.2010.24openalex-snapshot
Case Report of a Serious Adverse Event Following the Administration of T Cells Transduced With a Chimeric Antigen Receptor Recognizing ERBB2
inferredcites →https://doi.org/10.1038/mt.2010.272openalex-snapshot
T Cells Targeting Carcinoembryonic Antigen Can Mediate Regression of Metastatic Colorectal Cancer but Induce Severe Transient Colitis
inferredcites →https://doi.org/10.1038/mt.2010.31openalex-snapshot
Treatment of Chronic Lymphocytic Leukemia With Genetically Targeted Autologous T Cells: Case Report of an Unforeseen Adverse Event in a Phase I Clinical Trial
inferredcites →https://doi.org/10.1038/mt.2013.17openalex-snapshot
Treatment of Metastatic Renal Cell Carcinoma With CAIX CAR-engineered T cells: Clinical Evaluation and Management of On-target Toxicity
inferredcites →https://doi.org/10.1038/nm.1882openalex-snapshot
Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma
inferredcites →https://doi.org/10.1038/nm0296-216openalex-snapshot
T–cell mediated rejection of gene–modified HIV–specific cytotoxic T lymphocytes in HIV–infected patients
inferredcites →https://doi.org/10.1038/nrc3245openalex-snapshot
The immune contexture in human tumours: impact on clinical outcome
inferredcites →https://doi.org/10.1038/nri3191openalex-snapshot
Adoptive immunotherapy for cancer: harnessing the T cell response
inferredcites →https://doi.org/10.1038/nrurol.2010.57openalex-snapshot
Treatment of metastatic renal cell carcinoma
inferredcites →https://doi.org/10.1038/sj.gt.3302794openalex-snapshot
A guanylate kinase/HSV-1 thymidine kinase fusion protein enhances prodrug-mediated cell killing
inferredcites →https://doi.org/10.1038/sj.mt.6300190openalex-snapshot
The Suicide Gene Therapy Challenge: How to Improve a Successful Gene Therapy Approach
inferredcites →https://doi.org/10.1056/nejm200301163480314openalex-snapshot
A Serious Adverse Event after Successful Gene Therapy for X-Linked Severe Combined Immunodeficiency
inferredcites →https://doi.org/10.1056/nejmoa063842openalex-snapshot
Cytokine Storm in a Phase 1 Trial of the Anti-CD28 Monoclonal Antibody TGN1412
inferredcites →https://doi.org/10.1056/nejmoa0911123openalex-snapshot
Anti-GD2 Antibody with GM-CSF, Interleukin-2, and Isotretinoin for Neuroblastoma
inferredcites →https://doi.org/10.1056/nejmoa1000164openalex-snapshot
Efficacy of Gene Therapy for X-Linked Severe Combined Immunodeficiency
inferredcites →https://doi.org/10.1056/nejmoa1003466openalex-snapshot
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
inferredcites →https://doi.org/10.1056/nejmoa1103849openalex-snapshot
Chimeric Antigen Receptor–Modified T Cells in Chronic Lymphoid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1106152openalex-snapshot
Inducible Apoptosis as a Safety Switch for Adoptive Cell Therapy
inferredcites →https://doi.org/10.1056/nejmoa1215134openalex-snapshot
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
inferredcites →https://doi.org/10.1056/nejmoa1305133openalex-snapshot
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
inferredcites →https://doi.org/10.1056/nejmp058315openalex-snapshot
Herceptin and the Heart — A Molecular Modifier of Cardiac Failure
inferredcites →https://doi.org/10.1073/pnas.0405730101openalex-snapshot
Cancer regression in patients with metastatic melanoma after the transfer of autologous antitumor lymphocytes
inferredcites →https://doi.org/10.1073/pnas.0507496103openalex-snapshot
Retroviral vector integration deregulates gene expression but has no consequence on the biology and function of transplanted T cells
inferredcites →https://doi.org/10.1073/pnas.95.18.10437openalex-snapshot
Redesigning an FKBP–ligand interface to generate chemical dimerizers with novel specificity
inferredcites →https://doi.org/10.1080/14653240600620176openalex-snapshot
Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma
inferredcites →https://doi.org/10.1089/hgtb.2012.050openalex-snapshot
Comparison of Different Suicide-Gene Strategies for the Safety Improvement of Genetically Manipulated T Cells
inferredcites →https://doi.org/10.1093/annonc/mdt161openalex-snapshot
Four-year survival rates for patients with metastatic melanoma who received ipilimumab in phase II clinical trials
inferredcites →https://doi.org/10.1093/jnci/djq009openalex-snapshot
Interferon Alpha Adjuvant Therapy in Patients With High-Risk Melanoma: A Systematic Review and Meta-analysis
inferredcites →https://doi.org/10.1097/cji.0000000000000061openalex-snapshot
BRAF and MEK Inhibition Variably Affect GD2-specific Chimeric Antigen Receptor (CAR) T-Cell Function In Vitro
inferredcites →https://doi.org/10.1097/cji.0b013e318270dec7openalex-snapshot
Phenotypic and Functional Attributes of Lentivirus-modified CD19-specific Human CD8+ Central Memory T Cells Manufactured at Clinical Scale
inferredcites →https://doi.org/10.1097/cji.0b013e3182829903openalex-snapshot
Cancer Regression and Neurological Toxicity Following Anti-MAGE-A3 TCR Gene Therapy
inferredcites →https://doi.org/10.1097/ppo.0000000000000035openalex-snapshot
Managing Cytokine Release Syndrome Associated With Novel T Cell-Engaging Therapies
inferredcites →https://doi.org/10.1126/science.1083413openalex-snapshot
Transcription Start Regions in the Human Genome Are Favored Targets for MLV Integration
inferredcites →https://doi.org/10.1126/scitranslmed.3002842openalex-snapshot
T Cells with Chimeric Antigen Receptors Have Potent Antitumor Effects and Can Establish Memory in Patients with Advanced Leukemia
inferredcites →https://doi.org/10.1126/scitranslmed.3003761openalex-snapshot
Decade-Long Safety and Function of Retroviral-Modified Chimeric Antigen Receptor T Cells
inferredcites →https://doi.org/10.1126/scitranslmed.3005930openalex-snapshot
CD19-Targeted T Cells Rapidly Induce Molecular Remissions in Adults with Chemotherapy-Refractory Acute Lymphoblastic Leukemia
inferredcites →https://doi.org/10.1158/1078-0432.ccr-12-1092openalex-snapshot
A Pharmacokinetic/Pharmacodynamic Model of Tumor Lysis Syndrome in Chronic Lymphocytic Leukemia Patients Treated with Flavopiridol
inferredcites →https://doi.org/10.1158/1078-0432.ccr-13-0380openalex-snapshot
Adoptive Transfer of Tumor-Infiltrating Lymphocytes in Patients with Metastatic Melanoma: Intent-to-Treat Analysis and Efficacy after Failure to Prior Immunotherapies
inferredcites →https://doi.org/10.1159/000453569openalex-snapshot
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
inferredcites →https://doi.org/10.1159/000455014openalex-snapshot
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
inferredcites →https://doi.org/10.1172/jci46110openalex-snapshot
CD28 costimulation improves expansion and persistence of chimeric antigen receptor–modified T cells in lymphoma patients
inferredcites →https://doi.org/10.1177/00912700122010771openalex-snapshot
Intravenous Safety and Pharmacokinetics of a Novel Dimerizer Drug, AP1903, in Healthy Volunteers
inferredcites →https://doi.org/10.1182/blood-2004-11-4564openalex-snapshot
An inducible caspase 9 safety switch for T-cell therapy
inferredcites →https://doi.org/10.1182/blood-2005-08-3503openalex-snapshot
Analysis of transgene-specific immune responses that limit the in vivo persistence of adoptively transferred HSV-TK–modified donor T cells after allogeneic hematopoietic cell transplantation
inferredcites →https://doi.org/10.1182/blood-2007-01-068759openalex-snapshot
Hot spots of retroviral integration in human CD34+ hematopoietic cells
inferredcites →https://doi.org/10.1182/blood-2007-02-072843openalex-snapshot
Co-expression of cytokine and suicide genes to enhance the activity and safety of tumor-specific cytotoxic T lymphocytes
inferredcites →https://doi.org/10.1182/blood-2007-12-128751openalex-snapshot
Resistance of mature T cells to oncogene transformation
inferredcites →https://doi.org/10.1182/blood-2009-03-211714openalex-snapshot
Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen
inferredcites →https://doi.org/10.1182/blood-2009-08-239186openalex-snapshot
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients
inferredcites →https://doi.org/10.1182/blood-2011-04-348540openalex-snapshot
Safety and persistence of adoptively transferred autologous CD19-targeted T cells in patients with relapsed or chemotherapy refractory B-cell leukemias
inferredcites →https://doi.org/10.1182/blood-2011-05-354449openalex-snapshot
Antitumor activity and long-term fate of chimeric antigen receptor–positive T cells in patients with neuroblastoma
inferredcites →https://doi.org/10.1182/blood-2011-10-384388openalex-snapshot
B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor–transduced T cells
inferredcites →https://doi.org/10.1182/blood-2013-02-485623openalex-snapshot
Cytokine release syndrome after blinatumomab treatment related to abnormal macrophage activation and ameliorated with cytokine-directed therapy
inferredcites →https://doi.org/10.1182/blood-2013-03-490565openalex-snapshot
Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma
inferredcites →https://doi.org/10.1182/blood-2013-11-492231openalex-snapshot
Antibody-modified T cells: CARs take the front seat for hematologic malignancies
inferredcites →https://doi.org/10.1182/blood-2014-01-551671openalex-snapshot
Long-term outcome after haploidentical stem cell transplant and infusion of T cells expressing the inducible caspase 9 safety transgene
inferredcites →https://doi.org/10.1200/jco.1994.12.1.184openalex-snapshot
Phase I trial of murine monoclonal antibody 14G2a administered by prolonged intravenous infusion in patients with neuroectodermal tumors.
inferredcites →https://doi.org/10.1200/jco.2006.05.9964openalex-snapshot
Treatment of Metastatic Renal Cell Carcinoma With Autologous T-Lymphocytes Genetically Retargeted Against Carbonic Anhydrase IX: First Clinical Experience
inferredcites →https://doi.org/10.1200/jco.2013.53.0105openalex-snapshot
Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab
inferredcites →https://doi.org/10.1371/journal.pone.0082742openalex-snapshot
Combining a CD20 Chimeric Antigen Receptor and an Inducible Caspase 9 Suicide Switch to Improve the Efficacy and Safety of T Cell Adoptive Immunotherapy for Lymphoma
inferredcites →https://doi.org/10.1517/14712598.2011.565325openalex-snapshot
Gene-modified T lymphocytes in the setting of hematopoietic cell transplantation: potential benefits and possible risks
inferredcites →https://doi.org/10.1634/theoncologist.10-5-345openalex-snapshot
HER1/EGFR Inhibitor-Associated Rash: Future Directions for Management and Investigation Outcomes from the HER1/EGFR Inhibitor Rash Management Forum
inferredcites →https://doi.org/10.2119/molmed.2010.00193openalex-snapshot
Retroviral Insertional Mutagenesis Can Contribute to Immortalization of Mature T Lymphocytes
inferredcites →https://doi.org/10.4049/jimmunol.1490019openalex-snapshot
IL-2: The First Effective Immunotherapy for Human Cancer
inferredcites →https://doi.org/10.4049/jimmunol.180.9.6365openalex-snapshot
An Inducible Caspase 9 Safety Switch Can Halt Cell Therapy-Induced Autoimmune Disease
What points at this work
Incoming claims: where this work appears in other papers’ reference lists and arguments.
inferred← citeshttps://doi.org/10.2139/ssrn.4818803openalex-extracted
Roles of Ipsc in Advancing Treatments for Neurological Disorders
inferred← citeshttps://doi.org/10.1002/adfm.201701183openalex-snapshot
Engineered Axonal Tracts as “Living Electrodes” for Synaptic‐Based Modulation of Neural Circuitry
inferred← citeshttps://doi.org/10.1002/adfm.201904345openalex-snapshot
Engineering Molecular Machines for the Control of Cellular Functions for Diagnostics and Therapeutics
inferred← citeshttps://doi.org/10.1002/adfm.201910442openalex-snapshot
Controlled Apoptosis of Stromal Cells to Engineer Human Microlivers
inferred← citeshttps://doi.org/10.1002/adma.202007421openalex-snapshot
Materials for Improving Immune Cell Transfection
inferred← citeshttps://doi.org/10.1002/advs.201801039openalex-snapshot
Engineering Precision Medicine
inferred← citeshttps://doi.org/10.1002/ange.201601902openalex-snapshot
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer
inferred← citeshttps://doi.org/10.1002/ange.202109550openalex-snapshot
A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**
inferred← citeshttps://doi.org/10.1002/anie.201601902openalex-snapshot
Design of Switchable Chimeric Antigen Receptor T Cells Targeting Breast Cancer
inferred← citeshttps://doi.org/10.1002/anie.202109550openalex-snapshot
A Reversible Chemogenetic Switch for Chimeric Antigen Receptor T Cells**
inferred← citeshttps://doi.org/10.1002/cbin.70152openalex-snapshot
CAR‐NK Cell Biology and Engineering for Solid Tumors, With a Focus on Lung Cancer
inferred← citeshttps://doi.org/10.1002/cmdc.202501088openalex-snapshot
Sculpting Cell Fate: The Expanding Universe of Nondegradative Proximity‐Inducing Tools
inferred← citeshttps://doi.org/10.1002/cncr.30491openalex-snapshot
Adoptive T cell therapy: An overview of obstacles and opportunities
inferred← citeshttps://doi.org/10.1002/cpt.3241openalex-snapshot
Clinical Pharmacology Considerations for the “ Off‐the‐Shelf ” Allogeneic Cell Therapies
inferred← citeshttps://doi.org/10.1002/cti2.1050openalex-snapshot
Clinical chimeric antigen receptor‐T cell therapy: a new and promising treatment modality for glioblastoma
inferred← citeshttps://doi.org/10.1002/cti2.1147openalex-snapshot
Development and characterisation of NKp44‐based chimeric antigen receptors that confer T cells with NK cell‐like specificity
inferred← citeshttps://doi.org/10.1002/ctm2.70140openalex-snapshot
Enhancement of anti‐sarcoma immunity by NK cells engineered with mRNA for expression of a EphA2‐targeted CAR
inferred← citeshttps://doi.org/10.1002/iid3.70298openalex-snapshot
Chimeric Antigen Receptor T‐Cell Therapy and Autoimmune Diseases in the Nervous System
inferred← citeshttps://doi.org/10.1002/ijc.31147openalex-snapshot
Chimeric antigen receptor transduced T cells: Tuning up for the next generation
inferred← citeshttps://doi.org/10.1002/ijc.34635openalex-snapshot
Mechanisms and strategies for safe chimeric antigen receptor T‐cell activity control
inferred← citeshttps://doi.org/10.1002/jcb.30413openalex-snapshot
An overview of programmed cell death: Apoptosis and pyroptosis—Mechanisms, differences, and significance in organism physiology and pathophysiology
inferred← citeshttps://doi.org/10.1002/onco.13575openalex-snapshot
Emerging Immunotherapies in the Treatment of Brain Metastases
inferred← citeshttps://doi.org/10.1002/stem.2407openalex-snapshot
Concise Review: One Stone for Multiple Birds: Generating Universally Compatible Human Embryonic Stem Cells
inferred← citeshttps://doi.org/10.1002/wnan.1557openalex-snapshot
Applications of molecular engineering in T‐cell‐based immunotherapies
inferred← citeshttps://doi.org/10.1002/wsbm.1345openalex-snapshot
Engineering of synthetic gene circuits for (re‐)balancing physiological processes in chronic diseases
inferred← citeshttps://doi.org/10.1007/16833_2022_64openalex-snapshot
Recent Innovative Approaches to Intensify the Efficacy and Safety of CAR-T Cell Therapy in Cancers
inferred← citeshttps://doi.org/10.1007/978-1-0716-0759-6_14openalex-snapshot
Chimeric Antigen Receptor (CAR) T Cell Therapy for Cancer. Challenges and Opportunities: An Overview
inferred← citeshttps://doi.org/10.1007/978-1-0716-3666-4_12openalex-snapshot
Mammalian Antigen Display for Pandemic Countermeasures
inferred← citeshttps://doi.org/10.1007/978-3-030-24100-1_9openalex-snapshot
CAR-T cell and Personalized Medicine
inferred← citeshttps://doi.org/10.1007/978-3-030-53626-8_55openalex-snapshot
T-Cell Therapeutics: Donor Lymphocyte Infusion, Cytotoxic T-Lymphocyte Infusion, and Other Non-CAR T-Cell Therapies
inferred← citeshttps://doi.org/10.1007/978-3-030-57949-4_7openalex-snapshot
Immunopathology and Immunotherapy of Non-Hodgkin Lymphoma
inferred← citeshttps://doi.org/10.1007/978-3-030-58174-9_15openalex-snapshot
Industrial Perspective on Immunotherapy
inferred← citeshttps://doi.org/10.1007/978-3-030-94353-0_1openalex-snapshot
Structure of and Signalling Through Chimeric Antigen Receptor
inferred← citeshttps://doi.org/10.1007/978-3-030-98596-7_8openalex-snapshot
CAR-T Cells and Other Related Technologies
inferred← citeshttps://doi.org/10.1007/978-3-031-62007-2_19openalex-snapshot
Emerging Biopharmaceutical Technologies and Trends
inferred← citeshttps://doi.org/10.1007/978-3-662-46410-6_7openalex-snapshot
Immunopathology and Immunotherapy of Hodgkin Lymphoma
inferred← citeshttps://doi.org/10.1007/978-981-95-3628-3_1openalex-snapshot
History and Evolution of CAR T-Cell Therapy
inferred← citeshttps://doi.org/10.1007/978-981-95-3628-3_3openalex-snapshot
Engineering CAR T Cells: Advances in Vector Design and Gene Editing
inferred← citeshttps://doi.org/10.1007/978-981-95-3957-4_22openalex-snapshot
Synthetic Biology-Based Diagnostic Tools
inferred← citeshttps://doi.org/10.1007/s00005-018-0507-9openalex-snapshot
Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells
inferred← citeshttps://doi.org/10.1007/s00277-023-05227-0openalex-snapshot
Functional Validation of the RQR8 Suicide /Marker Gene in CD19 CAR-T Cells and CLL1CAR-T Cells
inferred← citeshttps://doi.org/10.1007/s00432-021-03839-5openalex-snapshot
GD2-specific chimeric antigen receptor-modified T cells for the treatment of refractory and/or recurrent neuroblastoma in pediatric patients
inferred← citeshttps://doi.org/10.1007/s10555-024-10185-8openalex-snapshot
In vivo manufacture and manipulation of CAR-T cells for better druggability
inferred← citeshttps://doi.org/10.1007/s11427-016-5025-6openalex-snapshot
Treatment of solid tumors with chimeric antigen receptor-engineered T cells: current status and future prospects
inferred← citeshttps://doi.org/10.1007/s12015-021-10246-3openalex-snapshot
Chimeric Antigen Receptor-Engineered Natural Killer (CAR NK) Cells in Cancer Treatment; Recent Advances and Future Prospects
inferred← citeshttps://doi.org/10.1007/s12016-026-09205-yopenalex-snapshot
Ataxia-Telangiectasia, DNA Repair Deficits, Immune Dysfunction, and Cancer: A Review of Mechanisms, Clinical Presentations, and Emerging Therapies
inferred← citeshttps://doi.org/10.1007/s12032-018-1149-9openalex-snapshot
Challenges and prospects of chimeric antigen receptor T cell therapy in solid tumors
inferred← citeshttps://doi.org/10.1007/s12032-025-03040-5openalex-snapshot
Chimeric antigen receptor T-cell (CAR T-cell) and tumor-infiltrating lymphocytes (TILs) therapies in gastrointestinal malignancies: review of literature for clinical applications
inferred← citeshttps://doi.org/10.1007/s12094-026-04313-9openalex-snapshot
Engineering the next generation of cellular therapies for solid tumors: multi-specific armored CARs and TME reprogramming strategies
inferred← citeshttps://doi.org/10.1007/s12272-016-0719-7openalex-snapshot
Current status and regulatory perspective of chimeric antigen receptor-modified T cell therapeutics
inferred← citeshttps://doi.org/10.1007/s12672-025-03876-3openalex-snapshot
FAM168B identified as a novel candidate target for chimeric antigen receptor T cell-based cancer therapy
inferred← citeshttps://doi.org/10.1007/s12672-025-04158-8openalex-snapshot
Ganglioside therapy in cancer molecular insights and therapeutic opportunities
inferred← citeshttps://doi.org/10.1007/s12672-026-05523-xopenalex-snapshot
Engineered immune cells and extracellular vesicles target tumour microenvironment barriers in solid tumour immunotherapy
inferred← citeshttps://doi.org/10.1007/s13237-017-0194-7openalex-snapshot
Cancer-immune therapy: restoration of immune response in cancer by immune cell modulation
inferred← citeshttps://doi.org/10.1007/s13402-025-01056-7openalex-snapshot
State of the art in CAR-based therapy: In vivo CAR production as a revolution in cell-based cancer treatment
inferred← citeshttps://doi.org/10.1007/s40259-015-0122-9openalex-snapshot
Chimeric Antigen Receptor-Engineered T Cells for the Treatment of Metastatic Prostate Cancer
inferred← citeshttps://doi.org/10.1007/s40259-017-0247-0openalex-snapshot
Next-Generation Chimeric Antigen Receptor T-Cell Therapy: Going off the Shelf
inferred← citeshttps://doi.org/10.1007/s40259-019-00354-5openalex-snapshot
Immunogenicity of Chimeric Antigen Receptor T-Cell Therapeutics
inferred← citeshttps://doi.org/10.1007/s40259-020-00412-3openalex-snapshot
In Vivo Delivery of Nucleic Acid-Encoded Monoclonal Antibodies
inferred← citeshttps://doi.org/10.1007/s40778-017-0101-9openalex-snapshot
CAR T Cells for Solid Tumors
inferred← citeshttps://doi.org/10.1007/s44466-025-00007-zopenalex-snapshot
Leveraging T cells for cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/b978-0-12-812034-7.00012-1openalex-snapshot
CAR-T Cell Clinical Trials Experience – Past, Present and Future
inferred← citeshttps://doi.org/10.1016/b978-0-12-819573-4.00002-8openalex-snapshot
Components and Design of Chimeric Antigen Receptors
inferred← citeshttps://doi.org/10.1016/b978-0-12-819573-4.00005-3openalex-snapshot
Challenges and Opportunities to Improve CAR T-Cell Therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-47674-4.00029-3openalex-snapshot
Gene Therapy in Oncology
inferred← citeshttps://doi.org/10.1016/b978-0-323-66181-2.00006-8openalex-snapshot
Special Considerations for ICU Management of Patients Receiving CAR Therapy
inferred← citeshttps://doi.org/10.1016/b978-0-323-95702-1.00295-5openalex-snapshot
Neurological Complications of Cancer Immunotherapy (CAR T-Cells)
inferred← citeshttps://doi.org/10.1016/b978-0-443-23571-9.00048-7openalex-snapshot
Living donor organ transplantation—gene therapy
inferred← citeshttps://doi.org/10.1016/bs.apcsb.2024.02.003openalex-snapshot
Recent advances in CAR T-cell engineering using synthetic biology: Paving the way for next-generation cancer treatment
inferred← citeshttps://doi.org/10.1016/bs.ircmb.2018.06.003openalex-snapshot
Engineering Platforms for T Cell Modulation
inferred← citeshttps://doi.org/10.1016/bs.mcb.2021.11.003openalex-snapshot
Strategies for manufacturing cell therapy products aligned with patient needs
inferred← citeshttps://doi.org/10.1016/bs.pmbts.2019.06.015openalex-snapshot
Synergistic combination of oncolytic virotherapy with CAR T-cell therapy
inferred← citeshttps://doi.org/10.1016/j.adcanc.2022.100035openalex-snapshot
Chimeric antigen receptor T cell structure, its manufacturing, and related toxicities; A comprehensive review
inferred← citeshttps://doi.org/10.1016/j.addr.2016.05.019openalex-snapshot
Engineering cell-based therapies to interface robustly with host physiology
inferred← citeshttps://doi.org/10.1016/j.apsb.2020.10.020openalex-snapshot
CAR-T cells: Early successes in blood cancer and challenges in solid tumors
inferred← citeshttps://doi.org/10.1016/j.apsb.2025.10.019openalex-snapshot
Immunocyte reprogramming empowers live-cell drug delivery: Mechanistic insights, delivery strategies, and clinical perspectives
inferred← citeshttps://doi.org/10.1016/j.beha.2018.04.002openalex-snapshot
Pre-clinical development of chimeric antigen receptor T-cell immunotherapy: Implications of design for efficacy and safety
inferred← citeshttps://doi.org/10.1016/j.biomaterials.2019.119265openalex-snapshot
T cell immunotherapy enhanced by designer biomaterials
inferred← citeshttps://doi.org/10.1016/j.blre.2018.11.002openalex-snapshot
Recent advances in CAR T-cell toxicity: Mechanisms, manifestations and management
inferred← citeshttps://doi.org/10.1016/j.blre.2024.101241openalex-snapshot
Advancing CAR T-cell therapies: Preclinical insights and clinical translation for hematological malignancies
inferred← citeshttps://doi.org/10.1016/j.canlet.2016.12.037openalex-snapshot
Recent clinical trials utilizing chimeric antigen receptor T cells therapies against solid tumors
inferred← citeshttps://doi.org/10.1016/j.canlet.2020.07.044openalex-snapshot
CAR T-cell therapy for triple-negative breast cancer: Where we are
inferred← citeshttps://doi.org/10.1016/j.canlet.2021.01.014openalex-snapshot
Tumor-tagging by oncolytic viruses: A novel strategy for CAR-T therapy against solid tumors
inferred← citeshttps://doi.org/10.1016/j.cell.2024.11.017openalex-snapshot
Synthetic organizer cells guide development via spatial and biochemical instructions
inferred← citeshttps://doi.org/10.1016/j.cellimm.2019.103963openalex-snapshot
Conjugated CAR T cell one step beyond conventional CAR T cell for a promising cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.clml.2020.08.027openalex-snapshot
Chimeric Antigen Receptor T-cell Therapy for Multiple Myeloma
inferred← citeshttps://doi.org/10.1016/j.cnsns.2026.109937openalex-snapshot
Delay-diffusion induced mode-selective Hopf bifurcations in a paradoxical cell population control circuit
inferred← citeshttps://doi.org/10.1016/j.cobme.2022.100372openalex-snapshot
Synthetic biology-based optimization of T cell immunotherapies for cancer
inferred← citeshttps://doi.org/10.1016/j.coi.2021.07.002openalex-snapshot
Safety switches for adoptive cell therapy
inferred← citeshttps://doi.org/10.1016/j.copbio.2018.01.029openalex-snapshot
There's (still) plenty of room at the bottom
inferred← citeshttps://doi.org/10.1016/j.cpt.2026.09.004openalex-snapshot
Cardiotoxicity of Novel Hemato-Oncology Therapies: Mechanisms, Monitoring, and Multidisciplinary Management
inferred← citeshttps://doi.org/10.1016/j.critrevonc.2023.104200openalex-snapshot
Interleukin-1 receptor accessory protein (IL-1RAP): A magic bullet candidate for immunotherapy of human malignancies
inferred← citeshttps://doi.org/10.1016/j.ctrv.2025.103046openalex-snapshot
CAR-T cell therapy in hepatocellular carcinoma: from mechanistic insights to clinical translation
inferred← citeshttps://doi.org/10.1016/j.cyto.2022.155920openalex-snapshot
Engineering off-the-shelf universal CAR T cells: A silver lining in the cloud
inferred← citeshttps://doi.org/10.1016/j.ejca.2023.113347openalex-snapshot
Adoptive cell therapy in paediatric extracranial solid tumours: current approaches and future challenges
inferred← citeshttps://doi.org/10.1016/j.ejphar.2021.174138openalex-snapshot
The effect of caspase-9 in the differentiation of SH-SY5Y cells
inferred← citeshttps://doi.org/10.1016/j.ejphar.2026.179102openalex-snapshot
HSP70: From molecular chaperone to integrative hub in castration-resistant prostate cancer therapeutic resistance
inferred← citeshttps://doi.org/10.1016/j.genrep.2023.101782openalex-snapshot
Transplantation immune responses: Biology, challenges, and opportunities using biomaterials
inferred← citeshttps://doi.org/10.1016/j.hbpd.2018.05.005openalex-snapshot
Chimeric antigen receptor-engineered T-cell therapy for liver cancer
inferred← citeshttps://doi.org/10.1016/j.htct.2023.05.009openalex-snapshot
Novelty in improvement of CAR T cell-based immunotherapy with the aid of CRISPR system
inferred← citeshttps://doi.org/10.1016/j.intimp.2026.117280openalex-snapshot
The role of chimeric antigen receptor (CAR) T cell therapy in breast cancer
inferred← citeshttps://doi.org/10.1016/j.it.2015.06.004openalex-snapshot
Engineering CAR-T cells: Design concepts
inferred← citeshttps://doi.org/10.1016/j.jconrel.2019.12.047openalex-snapshot
Current challenges and emerging opportunities of CAR-T cell therapies
inferred← citeshttps://doi.org/10.1016/j.jconrel.2026.114752openalex-snapshot
Thermal sonogenetics for adoptive cell transfer therapy
inferred← citeshttps://doi.org/10.1016/j.jcyt.2014.12.002openalex-snapshot
Different cytokine and stimulation conditions influence the expansion and immune phenotype of third-generation chimeric antigen receptor T cells specific for tumor antigen GD2
inferred← citeshttps://doi.org/10.1016/j.jcyt.2021.07.014openalex-snapshot
Conditional control of chimeric antigen receptor T-cell activity through a destabilizing domain switch and its chemical ligand
inferred← citeshttps://doi.org/10.1016/j.jgg.2020.01.002openalex-snapshot
Engineering T cells for immunotherapy of primary human hepatocellular carcinoma
inferred← citeshttps://doi.org/10.1016/j.jmb.2025.169184openalex-snapshot
A F420-dependent Single Domain Chemogenetic Tool for Protein De-dimerization
inferred← citeshttps://doi.org/10.1016/j.jns.2021.117405openalex-snapshot
Neurological complications of cancer immunotherapy (CAR T cells)
inferred← citeshttps://doi.org/10.1016/j.lfs.2020.118300openalex-snapshot
CAR-T in solid tumors: Blazing a new trail through the brambles
inferred← citeshttps://doi.org/10.1016/j.medj.2025.100992openalex-snapshot
Toward precision immunotherapy: In vivo gene editing of T, NK, and myeloid cells
inferred← citeshttps://doi.org/10.1016/j.molimm.2017.03.017openalex-snapshot
Modification of cytokine-induced killer cells with folate receptor alpha (FRα)-specific chimeric antigen receptors enhances their antitumor immunity toward FRα-positive ovarian cancers
inferred← citeshttps://doi.org/10.1016/j.omtm.2022.05.011openalex-snapshot
Targeted biallelic integration of an inducible Caspase 9 suicide gene in iPSCs for safer therapies
inferred← citeshttps://doi.org/10.1016/j.omtm.2023.06.007openalex-snapshot
A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell transfer applications
inferred← citeshttps://doi.org/10.1016/j.omtm.2025.101486openalex-snapshot
Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection
inferred← citeshttps://doi.org/10.1016/j.omto.2020.08.005openalex-snapshot
CAR-T Cells Targeting Epstein-Barr Virus gp350 Validated in a Humanized Mouse Model of EBV Infection and Lymphoproliferative Disease
inferred← citeshttps://doi.org/10.1016/j.omton.2025.200944openalex-snapshot
Development of multivalent CAR T cells as dual immunotherapy and conditioning agents
inferred← citeshttps://doi.org/10.1016/j.pan.2020.02.006openalex-snapshot
Pancreatic Cancer UK Grand Challenge: Developments and challenges for effective CAR T cell therapy for pancreatic ductal adenocarcinoma
inferred← citeshttps://doi.org/10.1016/j.retram.2024.103488openalex-snapshot
CAR-iNKT cell therapy: mechanisms, advantages, and challenges
inferred← citeshttps://doi.org/10.1016/j.semcancer.2017.02.010openalex-snapshot
The cancer-immunity cycle as rational design for synthetic cancer drugs: Novel DC vaccines and CAR T-cells
inferred← citeshttps://doi.org/10.1016/j.smim.2020.101390openalex-snapshot
Recent advances in tumor associated carbohydrate antigen based chimeric antigen receptor T cells and bispecific antibodies for anti-cancer immunotherapy
inferred← citeshttps://doi.org/10.1016/j.stemcr.2015.07.011openalex-snapshot
A Safeguard System for Induced Pluripotent Stem Cell-Derived Rejuvenated T Cell Therapy
inferred← citeshttps://doi.org/10.1016/j.stemcr.2023.09.010openalex-snapshot
Universal cell donor lines: A review of the current research
inferred← citeshttps://doi.org/10.1016/j.tranon.2021.101070openalex-snapshot
Remote controlling of CAR-T cells and toxicity management: Molecular switches and next generation CARs
inferred← citeshttps://doi.org/10.1016/j.transci.2023.103828openalex-snapshot
Leukapheresis for CAR-T cell production and therapy
inferred← citeshttps://doi.org/10.1016/j.treopn.2026.05.004openalex-snapshot
Rewriting CAR-T fate through cytokine engineering
inferred← citeshttps://doi.org/10.1016/j.yexmp.2024.104898openalex-snapshot
Fate control engagement augments NK cell responses in LV/hu-IL-12 transduced sarcoma
inferred← citeshttps://doi.org/10.1016/j.ymthe.2018.03.003openalex-snapshot
Myeloid Conditioning with c-kit-Targeted CAR-T Cells Enables Donor Stem Cell Engraftment
inferred← citeshttps://doi.org/10.1016/j.ymthe.2020.08.003openalex-snapshot
A Functional Screening Strategy for Engineering Chimeric Antigen Receptors with Reduced On-Target, Off-Tumor Activation
inferred← citeshttps://doi.org/10.1016/j.ymthe.2020.10.008openalex-snapshot
Development of CAR T Cells Expressing a Suicide Gene Plus a Chimeric Antigen Receptor Targeting Signaling Lymphocytic-Activation Molecule F7
inferred← citeshttps://doi.org/10.1016/j.ymthe.2025.03.023openalex-snapshot
IFN-γ-mediated suppression of Caspase-7 exacerbates acute lung injury induced by CAR-T cells
inferred← citeshttps://doi.org/10.1016/j.ymthe.2026.04.036openalex-snapshot
IL-15 and IL-21 synergy improves anti-tumor efficacy of iPSC-derived cytotoxic T cells in solid tumors
inferred← citeshttps://doi.org/10.1016/j.ymthe.2026.07.041openalex-snapshot
CAR T cells secreting anti-EpCAM bispecific T cell engagers overcome tumor heterogeneity in targeting epithelial-originated carcinomas
inferred← citeshttps://doi.org/10.1021/acs.molpharmaceut.4c01502openalex-snapshot
Advances in T Cell-Based Cancer Immunotherapy: From Fundamental Mechanisms to Clinical Prospects
inferred← citeshttps://doi.org/10.1021/acsomega.5c12020openalex-snapshot
An In-Silico Study on the Design of Biological Controllers for Sepsis Regulation
inferred← citeshttps://doi.org/10.1021/acssynbio.9b00175openalex-snapshot
An AND-Gated Drug and Photoactivatable Cre-loxP System for Spatiotemporal Control in Cell-Based Therapeutics
inferred← citeshttps://doi.org/10.1038/cgt.2016.46openalex-snapshot
Chimeric antigen receptors for treatment of glioblastoma: a practical review of challenges and ways to overcome them
inferred← citeshttps://doi.org/10.1038/mt.2016.106openalex-snapshot
Translational Implications for Off-the-shelf Immune Cells Expressing Chimeric Antigen Receptors
inferred← citeshttps://doi.org/10.1038/mt.2016.63openalex-snapshot
GD2-specific CAR T Cells Undergo Potent Activation and Deletion Following Antigen Encounter but can be Protected From Activation-induced Cell Death by PD-1 Blockade
inferred← citeshttps://doi.org/10.1038/nrc.2016.97openalex-snapshot
Engineered T cells: the promise and challenges of cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41417-021-00336-2openalex-snapshot
Delivery technologies to engineer natural killer cells for cancer immunotherapy
inferred← citeshttps://doi.org/10.1038/s41417-024-00823-2openalex-snapshot
FGFR4-specific CAR-T cells with inducible caspase-9 suicide gene as an approach to treat rhabdomyosarcoma
inferred← citeshttps://doi.org/10.1038/s41467-020-20785-xopenalex-snapshot
Preclinical assessment of the efficacy and specificity of GD2-B7H3 SynNotch CAR-T in metastatic neuroblastoma
inferred← citeshttps://doi.org/10.1038/s41467-020-20812-xopenalex-snapshot
Direct allele introgression into pure chicken breeds using Sire Dam Surrogate (SDS) mating
inferred← citeshttps://doi.org/10.1038/s41467-022-32092-8openalex-snapshot
T cell receptor β-chain-targeting chimeric antigen receptor T cells against T cell malignancies
inferred← citeshttps://doi.org/10.1038/s41569-026-01265-zopenalex-snapshot
Cardiotoxicity of T cell immunotherapies
inferred← citeshttps://doi.org/10.1038/s41571-020-0427-6openalex-snapshot
CAR T cell therapies for patients with multiple myeloma
inferred← citeshttps://doi.org/10.1038/s41573-020-0064-xopenalex-snapshot
Next-generation stem cells — ushering in a new era of cell-based therapies
inferred← citeshttps://doi.org/10.1038/s41576-021-00329-9openalex-snapshot
Genetic engineering of T cells for immunotherapy
inferred← citeshttps://doi.org/10.1038/s41577-019-0200-1openalex-snapshot
Engineering universal cells that evade immune detection
inferred← citeshttps://doi.org/10.1038/s41585-021-00488-8openalex-snapshot
The potential of CAR T cell therapy for prostate cancer
inferred← citeshttps://doi.org/10.1038/s41586-020-2403-9openalex-snapshot
Senolytic CAR T cells reverse senescence-associated pathologies
inferred← citeshttps://doi.org/10.1038/s41587-019-0403-9openalex-snapshot
A computationally designed chimeric antigen receptor provides a small-molecule safety switch for T-cell therapy
inferred← citeshttps://doi.org/10.1038/s41587-025-02757-yopenalex-snapshot
Engineering B cells to treat and study human disease
inferred← citeshttps://doi.org/10.1038/s41592-018-0041-zopenalex-snapshot
StaPLs: versatile genetically encoded modules for engineering drug-inducible proteins
inferred← citeshttps://doi.org/10.1038/s41598-019-38752-yopenalex-snapshot
Structural basis for chemically-induced homodimerization of a single domain antibody
inferred← citeshttps://doi.org/10.1038/s41598-022-11021-1openalex-snapshot
High throughput screen for the improvement of inducible promoters for tumor microenvironment cues
inferred← citeshttps://doi.org/10.1038/s41598-024-65711-zopenalex-snapshot
Caspase-9 suppresses metastatic behavior of MDA-MB-231 cells in an adaptive organoid model
inferred← citeshttps://doi.org/10.1038/s42003-021-01664-7openalex-snapshot
Synthetic promoters to induce immune-effectors into the tumor microenvironment
inferred← citeshttps://doi.org/10.1038/s43587-023-00560-5openalex-snapshot
Prophylactic and long-lasting efficacy of senolytic CAR T cells against age-related metabolic dysfunction
inferred← citeshttps://doi.org/10.1038/s43587-025-01022-wopenalex-snapshot
Anti-uPAR CAR T cells reverse and prevent aging-associated defects in intestinal regeneration and fitness
inferred← citeshttps://doi.org/10.1038/s44161-025-00746-7openalex-snapshot
Development and modeling of cardiac autonomic innervation
inferred← citeshttps://doi.org/10.1039/d0nr02133dopenalex-snapshot
Identification of a moderate affinity CD22 binding peptide and in vitro optimization of peptide-targeted nanoparticles for selective uptake by CD22+ B-cell malignancies
inferred← citeshttps://doi.org/10.1039/d4bm00709copenalex-snapshot
Splittable systems in biomedical applications
inferred← citeshttps://doi.org/10.1042/bst20150280openalex-snapshot
Development of chimeric antigen receptors for multiple myeloma
inferred← citeshttps://doi.org/10.1042/bst20170178openalex-snapshot
Logic-gated approaches to extend the utility of chimeric antigen receptor T-cell technology
inferred← citeshttps://doi.org/10.1053/j.seminhematol.2025.11.001openalex-snapshot
Harnessing single-domain antibodies for CAR-T and bispecific antibody development
inferred← citeshttps://doi.org/10.1053/j.seminhematol.2025.12.001openalex-snapshot
Advances and challenges in CAR-T therapy for glioblastoma
inferred← citeshttps://doi.org/10.1063/5.0073746openalex-snapshot
Engineering CAR T cells for enhanced efficacy and safety
inferred← citeshttps://doi.org/10.1080/08830185.2022.2080820openalex-snapshot
CAR-T cells for cancer immunotherapy—the barriers ahead and the paths through
inferred← citeshttps://doi.org/10.1080/08830185.2022.2101647openalex-snapshot
Combinatorial approaches to effective therapy in glioblastoma (GBM): Current status and what the future holds
inferred← citeshttps://doi.org/10.1080/10428194.2017.1375107openalex-snapshot
Anti-CD123 chimeric antigen receptor T-cells (CART): an evolving treatment strategy for hematological malignancies, and a potential ace-in-the-hole against antigen-negative relapse
inferred← citeshttps://doi.org/10.1080/13543784.2016.1254616openalex-snapshot
Folate receptor alpha antagonists in preclinical and early stage clinical development for the treatment of epithelial ovarian cancer
inferred← citeshttps://doi.org/10.1080/14656566.2017.1340938openalex-snapshot
Novel therapy for childhood acute lymphoblastic leukemia
inferred← citeshttps://doi.org/10.1080/14712598.2017.1339687openalex-snapshot
Practical considerations for chimeric antigen receptor design and delivery
inferred← citeshttps://doi.org/10.1080/14712598.2017.1369948openalex-snapshot
T cell optimization for the treatment of pancreatic cancer
inferred← citeshttps://doi.org/10.1080/14712598.2018.1425679openalex-snapshot
Reprogramming T-cells for adoptive immunotherapy of ovarian cancer
inferred← citeshttps://doi.org/10.1080/14712598.2020.1727436openalex-snapshot
CAR T cells and checkpoint inhibition for the treatment of glioblastoma
inferred← citeshttps://doi.org/10.1080/14712598.2020.1819978openalex-snapshot
Emerging vistas in CAR T-cell therapy: challenges and opportunities in solid tumors
inferred← citeshttps://doi.org/10.1080/2162402x.2016.1251539openalex-snapshot
CAR-T cell therapy in gastrointestinal tumors and hepatic carcinoma: From bench to bedside
inferred← citeshttps://doi.org/10.1080/2162402x.2020.1825177openalex-snapshot
Adapter chimeric antigen receptor (AdCAR)-engineered NK-92 cells: an off-the-shelf cellular therapeutic for universal tumor targeting
inferred← citeshttps://doi.org/10.1080/21645515.2021.2016005openalex-snapshot
IL-6/IFN-γ double knockdown CAR-T cells reduce the release of multiple cytokines from PBMCs in vitro
inferred← citeshttps://doi.org/10.1083/jcb.202109038openalex-snapshot
Optogenetic activators of apoptosis, necroptosis, and pyroptosis
inferred← citeshttps://doi.org/10.1089/hum.2018.119openalex-snapshot
Induced CD20 Expression on B-Cell Malignant Cells Heightened the Cytotoxic Activity of Chimeric Antigen Receptor Engineered T Cells
inferred← citeshttps://doi.org/10.1089/hum.2025.052openalex-snapshot
Autologous Production: The Future of Sustainable Antibody Treatments
inferred← citeshttps://doi.org/10.1093/abt/tbaf019openalex-snapshot
CAR NK cell therapy for solid tumors: potential and challenges
inferred← citeshttps://doi.org/10.1093/annonc/mdx238openalex-snapshot
Mechanisms regulating T-cell infiltration and activity in solid tumors
inferred← citeshttps://doi.org/10.1093/jhered/esw050openalex-snapshot
Horizontal Transfer Can Drive a Greater Transposable Element Load in Large Populations
inferred← citeshttps://doi.org/10.1097/ccm.0000000000004087openalex-snapshot
Critical Care Management of Toxicities Associated With Targeted Agents and Immunotherapies for Cancer
inferred← citeshttps://doi.org/10.1097/cco.0000000000000653openalex-snapshot
New targets and technologies for CAR-T cells
inferred← citeshttps://doi.org/10.1097/cji.0000000000000286openalex-snapshot
Anti-αFR CAR-engineered NK-92 Cells Display Potent Cytotoxicity Against αFR-positive Ovarian Cancer
inferred← citeshttps://doi.org/10.1097/cm9.0000000000002944openalex-snapshot
Development of a novel HER2-CAR monocyte cell therapy with controllable proliferation and enhanced anti-tumor efficacy
inferred← citeshttps://doi.org/10.1097/js9.0000000000002919openalex-snapshot
Tumor immunotherapy: past, present, and future
inferred← citeshttps://doi.org/10.1097/mop.0000000000000436openalex-snapshot
Future directions in chimeric antigen receptor T cell therapy
inferred← citeshttps://doi.org/10.1101/2022.08.12.503781openalex-snapshot
SNAP-tag and HaloTag fused proteins for HaSX8-inducible control over synthetic biological functions in engineered mammalian cells
inferred← citeshttps://doi.org/10.1101/2022.10.31.514542openalex-snapshot
A method for polyclonal antigen-specific T cell-targeted genome editing (TarGET) for adoptive cell therapy applications
inferred← citeshttps://doi.org/10.1101/2024.03.19.585779openalex-snapshot
Senolytic CAR T cells reverse aging-associated defects in intestinal regeneration and fitness
inferred← citeshttps://doi.org/10.1101/2025.03.28.645780openalex-snapshot
An in vivo CRISPR screen unveils top target genes to improve CAR-T cell efficacy in a solid tumor model
inferred← citeshttps://doi.org/10.1109/tcyb.2025.3556585openalex-snapshot
Dynamic Analysis and Robust Strategy for the Delayed Paradoxical Cell Population Control Circuit
showing the first 200 of 391 · page through all 391
Editorial review for independent work. ICSAC — the Institute for Complexity
Science and Advanced Computing — runs a structured editorial panel for researchers
publishing outside journals, and publishes on CiteStamp rails. Submission is free
and goes through ORCID: icsacinstitute.org/submit.